## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.9% below STRENGTH zone (4.0-10.0%); PEG 3.79 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($95.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed**
- Source: PR Newswire | 20251219T210832 | Bullish | Relevance: 100%
- Medtronic plc announced that its Diabetes business, MiniMed, has filed a registration statement on Form S-1 with the SEC for a proposed initial public offering (IPO) of newly issued common stock. The separation is expected through capital markets transactions, with MiniMed applying to list its common stock on the Nasdaq Global Select Market under the symbol MMED. The IPO's details, including the number of shares and price range, are yet to be determined and are subject to SEC review and market conditions.

**2. Chesley Taft & Associates LLC Takes Position in Medtronic PLC $MDT**
- Source: MarketBeat | 20251219T092132 | Bullish | Relevance: 100%
- Chesley Taft & Associates LLC initiated a new position in Medtronic PLC (NYSE:MDT) during the third quarter, acquiring 11,237 shares valued at approximately $1.07 million. Medtronic recently beat Q3 earnings expectations with $1.36 EPS and $8.96 billion in revenue, and has declared a quarterly dividend of $0.71 per share. The medical technology company has an average analyst rating of "Moderate Buy" with an average price target of $109.94.

**3. Medtronic Diabetes unit MiniMed files for IPO**
- Source: MassDevice | 20251219T000834 | Somewhat-Bullish | Relevance: 100%
- Medtronic announced that its MiniMed Diabetes business has filed a registration statement with the SEC for a proposed initial public offering (IPO). MiniMed plans to separate from Medtronic through capital markets transactions, including an IPO, and list its common stock on the Nasdaq under the "MMED" ticker. The company has not yet determined the number of shares or price range for the IPO.

**4. Medtronic, J&J MedTech both get FDA nods for liquid embolic systems**
- Source: MassDevice | 20251218T152819 | Bullish | Relevance: 100%
- Medtronic and Johnson & Johnson MedTech have both received FDA approvals for their respective liquid embolic systems (LES) to treat symptomatic subacute and chronic Subdural Hematoma (cSDH) as an adjunct to surgery. Medtronic's Onyx LES and J&J MedTech's TruFill n-BCA LES demonstrated effectiveness in clinical trials, with Onyx showing decreased recurrence and re-operation rates and TruFill n-BCA proving superior to standard care. These approvals signify advancements in minimally invasive neurovascular treatment options.

**5. Medtronic (MDT) Plans IPO for MiniMed Diabetes Business**
- Source: GuruFocus | 20251219T221632 | Somewhat-Bullish | Relevance: 100%
- Medtronic plc (MDT) is moving forward with its strategic plan to spin off its MiniMed diabetes division via an initial public offering (IPO), having submitted a Form S-1 registration statement to the SEC. The new entity, "MMED", will list on the Nasdaq Global Select Market. This move aims to separate the diabetes business from Medtronic's larger portfolio, which boasts robust financial health and a diverse range of medical devices.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 8, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $107 | $110 | -3% |
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Hold |
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.79 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (8 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $126.5B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.79 |
| Forward P/E | 16.1 |
| Current P/E | 17.4 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -2.9% (minimal 5-day change). Below STRENGTH zone by 6.9pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram bearish (-0.64), momentum weakening. RSI neutral at 47. OFD pattern: +DBH (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.87% (CS: 22) | Weak |
| RSI_14 | 47.2 | Neutral |
| MACD Histogram | -0.64 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 1.014x | Above |
| vs SMA200 | 1.082x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $98.60
- **Stop Loss:** $95.32 (3.3% risk)
- **Target:** $101.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 365
- **Position Value:** $35,989.00
- **Portfolio %:** 35.99%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*